Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESAX-HTN study
jRCT2080223293Phase 3Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of esaxerenone in essential hypertension (3 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Change in sitting blood pressure from baseline to 12 weeks. Started Aug 2016; status: completed.
02
Drugs
esaxerenone
03
Conditions
essential hypertension
Beyond the preview
Go deeper on jRCT2080223293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223293.